Literature DB >> 24317870

Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics.

Hoai-Thu Thai1, France Mentré, Nicholas H G Holford, Christine Veyrat-Follet, Emmanuelle Comets.   

Abstract

Bootstrap methods are used in many disciplines to estimate the uncertainty of parameters, including multi-level or linear mixed-effects models. Residual-based bootstrap methods which resample both random effects and residuals are an alternative approach to case bootstrap, which resamples the individuals. Most PKPD applications use the case bootstrap, for which software is available. In this study, we evaluated the performance of three bootstrap methods (case bootstrap, nonparametric residual bootstrap and parametric bootstrap) by a simulation study and compared them to that of an asymptotic method (Asym) in estimating uncertainty of parameters in nonlinear mixed-effects models (NLMEM) with heteroscedastic error. This simulation was conducted using as an example of the PK model for aflibercept, an anti-angiogenic drug. As expected, we found that the bootstrap methods provided better estimates of uncertainty for parameters in NLMEM with high nonlinearity and having balanced designs compared to the Asym, as implemented in MONOLIX. Overall, the parametric bootstrap performed better than the case bootstrap as the true model and variance distribution were used. However, the case bootstrap is faster and simpler as it makes no assumptions on the model and preserves both between subject and residual variability in one resampling step. The performance of the nonparametric residual bootstrap was found to be limited when applying to NLMEM due to its failure to reflate the variance before resampling in unbalanced designs where the Asym and the parametric bootstrap performed well and better than case bootstrap even with stratification.

Mesh:

Substances:

Year:  2013        PMID: 24317870     DOI: 10.1007/s10928-013-9343-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  12 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

2.  Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians.

Authors:  J Carpenter; J Bithell
Journal:  Stat Med       Date:  2000-05-15       Impact factor: 2.373

3.  A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

Authors:  J Parke; N H Holford; B G Charles
Journal:  Comput Methods Programs Biomed       Date:  1999-04       Impact factor: 5.428

4.  Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.

Authors:  Ene I Ette; Leonard C Onyiah
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jul-Sep       Impact factor: 2.441

5.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

6.  Using SAS to conduct nonparametric residual bootstrap multilevel modeling with a small number of groups.

Authors:  Jichuan Wang; James R Carpenter; Michael A Kepler
Journal:  Comput Methods Programs Biomed       Date:  2006-03-29       Impact factor: 5.428

7.  Stability and performance of a population pharmacokinetic model.

Authors:  E I Ette
Journal:  J Clin Pharmacol       Date:  1997-06       Impact factor: 3.126

8.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

9.  A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models.

Authors:  Hoai-Thu Thai; France Mentré; Nicholas H G Holford; Christine Veyrat-Follet; Emmanuelle Comets
Journal:  Pharm Stat       Date:  2013-03-04       Impact factor: 1.894

10.  Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

Authors:  Rodryg Ramlau; Vera Gorbunova; Tudor Eliade Ciuleanu; Silvia Novello; Mustafa Ozguroglu; Tuncay Goksel; Clarissa Baldotto; Jaafar Bennouna; Frances A Shepherd; Solenn Le-Guennec; Augustin Rey; Vincent Miller; Nicholas Thatcher; Giorgio Scagliotti
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544

View more
  23 in total

1.  Malabsorption blood test: Assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiency.

Authors:  Maria R Mascarenhas; John Mondick; Jeffrey S Barrett; Martha Wilson; Virginia A Stallings; Joan I Schall
Journal:  J Clin Pharmacol       Date:  2015-03-23       Impact factor: 3.126

2.  Model Averaging in Viral Dynamic Models.

Authors:  Antonio Gonçalves; France Mentré; Annabelle Lemenuel-Diot; Jérémie Guedj
Journal:  AAPS J       Date:  2020-02-13       Impact factor: 4.009

3.  Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.

Authors:  Camille Couffignal; Olivier Pajot; Cédric Laouénan; Charles Burdet; Arnaud Foucrier; Michel Wolff; Laurence Armand-Lefevre; France Mentré; Laurent Massias
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

4.  Population pharmacokinetics of crenolanib in children and young adults with brain tumors.

Authors:  Cora Bisbee; Olivia Campagne; Amar Gajjar; Christopher L Tinkle; Clinton F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  2022-02-25       Impact factor: 3.333

5.  Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection.

Authors:  Romain Marlin; Mélanie Prague; Marie Alexandre; Severin Coleon; Nidhal Kahlaoui; Sylvain Cardinaud; Thibaut Naninck; Benoit Delache; Mathieu Surenaud; Mathilde Galhaut; Nathalie Dereuddre-Bosquet; Mariangela Cavarelli; Pauline Maisonnasse; Mireille Centlivre; Christine Lacabaratz; Aurelie Wiedemann; Sandra Zurawski; Gerard Zurawski; Olivier Schwartz; Rogier W Sanders; Roger Le Grand; Yves Levy; Rodolphe Thiébaut
Journal:  Elife       Date:  2022-07-08       Impact factor: 8.713

6.  Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas.

Authors:  Elizabeth G Gibson; Olivia Campagne; Nicholas S Selvo; Amar Gajjar; Clinton F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  2021-09-29       Impact factor: 3.333

7.  Dexmedetomidine Pharmacokinetics and a New Dosing Paradigm in Infants Supported With Cardiopulmonary Bypass.

Authors:  Kanecia O Zimmerman; Huali Wu; Matthew Laughon; Rachel G Greenberg; Richard Walczak; Scott R Schulman; P Brian Smith; Christoph P Hornik; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Anesth Analg       Date:  2019-12       Impact factor: 6.627

8.  Pharmacokinetics of Anti-VEGF Agent Aflibercept in Cancer Predicted by Data-Driven, Molecular-Detailed Model.

Authors:  S D Finley; P Angelikopoulos; P Koumoutsakos; A S Popel
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-10-09

9.  PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.

Authors:  Andrea Henrich; Pierre-Eric Juif; Jasper Dingemanse; Andreas Krause
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-01-02       Impact factor: 2.745

10.  Accelerating Monte Carlo power studies through parametric power estimation.

Authors:  Sebastian Ueckert; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-03-02       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.